Clinical trialPhase 2Completed
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
A Open-label, Single-arm, Single-center, Phase II Clinical Study of Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 30 January 2023
- Expected end
- 10 May 2025
- Enrollment
- 22 participants
- Sites
- 1
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 28 May 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer
Detailed description public domain (ClinicalTrials.gov)
surufatinib:250mg,QD,Q4W TAS-102:35mg/m2,D1-5,D8-12,Q4W